These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 8775469)

  • 1. Temporary resolution of obstructive jaundice during ursodeoxycholic acid therapy in a patient with primary sclerosing cholangitis and a dominant biliary stricture.
    Fracchia M; Soubrane O; Houssin D; Galatola G
    Ital J Gastroenterol; 1995; 27(8):430-5. PubMed ID: 8775469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A; Rudolph G; Sauer P; Theilmann L
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis.
    Rudolph G; Endele R; Senn M; Stiehl A
    Hepatology; 1993 Jun; 17(6):1028-32. PubMed ID: 8514251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
    Hay JE
    Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug therapy of cholestatic hepatopathies].
    Leuschner U
    Schweiz Rundsch Med Prax; 1992 Aug; 81(34):983-4. PubMed ID: 1529191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoscopic therapy in primary sclerosing cholangitis: outcome of treatment and risk of cancer.
    Linder S; Söderlund C
    Hepatogastroenterology; 2001; 48(38):387-92. PubMed ID: 11379315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.
    Rudolph G; Kloeters-Plachky P; Rost D; Stiehl A
    Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):487-91. PubMed ID: 17489059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment options for primary sclerosing cholangitis.
    Sinakos E; Lindor K
    Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):473-88. PubMed ID: 20678020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
    Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
    Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention of clogging of biliary stents by administration of levofloxacin and ursodeoxycholic acid].
    Sciumè C; Geraci G; Pisello F; Facella T; Li Volsi F; Modica G
    Chir Ital; 2004; 56(6):831-7. PubMed ID: 15771038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
    Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
    Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.
    Lindor KD
    N Engl J Med; 1997 Mar; 336(10):691-5. PubMed ID: 9041099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies.
    van Milligen de Wit AW; van Deventer SJ; Tytgat GN
    Am J Gastroenterol; 1995 Jun; 90(6):893-900. PubMed ID: 7771416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markedly elevated serum CA 19-9 levels in association with a benign biliary stricture due to primary sclerosing cholangitis.
    Murray MD; Burton FR; Di Bisceglie AM
    J Clin Gastroenterol; 2007 Jan; 41(1):115-7. PubMed ID: 17198074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary sclerosing cholangitis.
    Zein CO; Lindor KD
    Semin Gastrointest Dis; 2001 Apr; 12(2):103-12. PubMed ID: 11352117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-liver transplant cholestatic disorder with biliary strictures: de novo versus recurrent primary sclerosing cholangitis.
    McPartland KJ; Lewis WD; Gordon FD; Pomfret EA; Pomposelli JJ; Jenkins R; Khettry U
    Pathol Int; 2009 May; 59(5):312-6. PubMed ID: 19432673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerosing cholangitis.
    MacFaul GR; Chapman RW
    Curr Opin Gastroenterol; 2006 May; 22(3):288-93. PubMed ID: 16550044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
    Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
    Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
    Wolf JM; Rybicki LA; Lashner BA
    Aliment Pharmacol Ther; 2005 Nov; 22(9):783-8. PubMed ID: 16225486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.